Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review

被引:0
|
作者
Itay Lotan
Mark A. Hellmann
Adi Wilf-Yarkoni
Israel Steiner
机构
[1] Beilinson Hospital,Department of Neurology, Rabin Medical Center
[2] Beilinson Hospital,Neuroimmunology Unit, Rabin Medical Center
[3] Tel-Aviv University,Sackler Faculty of Medicine
来源
Journal of Neurology | 2021年 / 268卷
关键词
Myasthenia gravis; Corticosteroids; Initial exacerbation; Prednisone; Cortisone; Methylprednisolone;
D O I
暂无
中图分类号
学科分类号
摘要
Corticosteroids (CS) are among the most widely- used immunosuppressive agents for immune-mediated conditions, including myasthenia gravis (MG). While their effectiveness in MG is documented and supported in the clinical practice over several decades, one of the main drawbacks of treatment results from the notion that MG patients may experience symptom worsening following CS treatment initiation. This may lead to the administration of lower than necessary doses of CS for the disorder, or even avoiding them altogether. As a consequence, some patients may not receive the optimal treatment to control their disease. In the present review, we analyzed 27 relevant publications and determined the prevalence of clinical exacerbation following CS treatment, its’ severity and relation to the type and dose of CS. The rate of MG exacerbation is highest with the administration of cortisone, intermediate with prednisone, and lowest with methylprednisolone. High dose daily or alternate-day prednisone is associated with exacerbation more frequently than low-dose treatment, but most exacerbations are of mild to moderate severity. Other factors related to increased risk of an initial exacerbation include older age, generalized MG, bulbar symptoms, disease severity, presence of thymoma, and thymectomy. However, the current information is based mostly on heterogeneous studies of low quality, and prospective clinical trials designed to compare between the various agents and doses and assess the rate and severity of the exacerbation by a unified scale are warranted.
引用
收藏
页码:4573 / 4586
页数:13
相关论文
共 50 条
  • [31] The Incidence of Myasthenia Gravis: A Systematic Literature Review
    McGrogan, Anita
    Sneddon, Samantha
    de Vries, Corinne S.
    NEUROEPIDEMIOLOGY, 2010, 34 (03) : 171 - 183
  • [32] Course and prognosis of myasthenia gravis: a systematic review
    Mao, Z. -F.
    Mo, X. -A.
    Qin, C.
    Lai, Y. -R.
    Hartman, T. C. Olde
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (07) : 913 - 921
  • [33] Methotrexate in generalized myasthenia gravis: a systematic review
    Mario B. Prado
    Karen Joy B. Adiao
    Acta Neurologica Belgica, 2023, 123 : 1679 - 1691
  • [34] What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
    Vanoli, Fiammetta
    Mantegazza, Renato
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1471 - 1474
  • [35] Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
    Vu, Tuan
    Wiendl, Heinz
    Katsuno, Masahisa
    Reddel, Stephen W.
    Howard Jr, James F.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 2639 - 2655
  • [36] Effects of acupuncture treatment for myasthenia gravis: A systematic review and meta-analysis
    Xue, Hua
    Zeng, Li
    He, Hongxian
    Xu, Dongxun
    Ren, Kaixin
    PLOS ONE, 2024, 19 (01):
  • [37] THE EVOLUTIONARY SAGA OF CORTICOSTEROID IN MYASTHENIA GRAVIS AND WHAT WE HAVE LEARNT FROM THIS ...
    Bandyopadhyay, Sankar
    NEUROLOGY, 2017, 88
  • [38] THE EVOLUTIONARY SAGA OF CORTICOSTEROID IN MYASTHENIA GRAVIS AND WHAT WE HAVE LEARNT FROM THIS ...
    Bandyopadhyay, Sankar
    NEUROLOGY, 2017, 88
  • [39] Rituximab in AChR subtype of myasthenia gravis: systematic review
    Di Stefano, Vincenzo
    Lupica, Antonino
    Rispoli, Marianna Gabriella
    Di Muzio, Antonio
    Brighina, Filippo
    Rodolico, Carmelo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (04): : 392 - 395
  • [40] Acupuncture for patients with myasthenia gravis A systematic review protocol
    Shi, Shuai
    Ji, Xinyu
    Wang, Yanping
    Liu, Bin
    Zhang, Huamin
    Lu, Cheng
    MEDICINE, 2019, 98 (42) : e17563